With Deadline Looming, Novartis Yet To Reach Fee-For-Service Contracts
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis has not entered into fee-for-service contracts with any of its distributors, Novartis Pharmaceuticals CEO Paolo Costa said March 15
You may also be interested in...
McKesson Fee-For-Service Negotiations Encounter A Handful Of Holdouts
Approximately four of McKesson’s “larger manufacturer” partners have not reached, and are not in talks on, fee-for-service contracts. McKesson will not necessarily drop manufacturers that do not reach a formal agreement as long as the economics continue to work, CEO Hammergren says.
Pfizer Says No To "Fee-For-Service" Contracts With Wholesalers
The manufacturer maintains that wholesalers "purchase and resell products for their own account and not as a service to Pfizer." Cardinal will no longer distribute Eisai products, including the Alzheimer's drug Aricept, marketed in partnership with Pfizer.
Cardinal Fee-For-Service Ultimatum Has “Accelerated” Contracting, CEO Says
Cardinal's progress in signing fee-for-service distribution contracts with pharmaceutical manufacturers has "accelerated" since the wholesaler set a March 31 contract deadline